LabCorp 2014 Annual Report Download - page 121

Download and view the complete annual report

Please find page 121 of the 2014 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 128

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128

F-42
The Company believes these embedded derivatives had no fair value at December 31, 2014 and 2013. These embedded
derivatives also had no impact on the consolidated statements of operations for the years ended December 31, 2014, 2013 and
2012.
19. SUPPLEMENTAL CASH FLOW INFORMATION
Years Ended December 31,
2014 2013 2012
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest $ 117.8 $ 97.2 $ 77.5
Income taxes, net of refunds 284.1 301.5 306.2
Disclosure of non-cash financing and investing activities:
Surrender of restricted stock awards and performance shares 6.6 7.1 10.9
Conversion of zero-coupon convertible debt 9.9 10.3 3.8
Assets acquired under capital leases 29.0 13.1 —
Accrued property, plant and equipment 6.2 9.1 1.2
20. BUSINESS SEGMENT INFORMATION
The following table is a summary of segment information for the years ended December 31, 2014, 2013, and 2012.
Segment asset information is not presented because it is not used by the chief operating decision maker at the operating
segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at
operating income for the segment. General management and administrative corporate expenses are included in general
corporate expenses below.
Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial
clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other
medical conditions through the examination of substances in the blood, tissues and other specimens. Clinical diagnostics
laboratory segment includes financial information related to the broad range of testing services that are reported primarily
through the U.S. business operations. The other reportable segment includes the Company's non-U.S. clinical diagnostic
laboratory operations in Ontario, Canada, which are reviewed separately by corporate management for the purposes of
allocation of resources.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Dollars and shares in millions, except per share data)